Skip to main content
See every side of every news story
Published • loading... • Updated

Lilly to Buy Calytrix Bio for up to $1.5 Billion

The acquisition adds an experimental antibody program for rare blood cancers and could pay Calytrix shareholders up to $1.5 billion.

Summary by WTVB
Nov 16 (Reuters) - Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion ​in cash to expand ‌the development of treatments for rare blood cancers, the privately held biotech said on Monday. The move is the ‌latest ​in a string of ⁠acquisi...

10 Articles

Lean Right

For the US pharmaceutical company, the purchase is a further step away from the dependence on the business of weight loss.

·Düsseldorf, Germany
Read Full Article

The deal is expected to strengthen Lilly's presence in hematology.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 80% of the sources are Center
80% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news on Monday, November 16, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal